Paper17510371
Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model.
Taksir TV and 5 others. J Histochem Cytochem, 2007. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model. Papers, record 17510371. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17510371
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain | Major topic |
| Glycogen | Major topic |
| Glycogen Storage Disease Type II | Major topic |
| Tissue Fixation | Major topic |
| Animals | |
| Buffers | |
| Cerebellum | |
| Disease Models, Animal | |
| Fixatives | |
| Formaldehyde | |
| Mice | |
| Mice, Inbred C57BL | |
| Mice, Knockout | |
| Paraffin Embedding | |
| Periodic Acid |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42130276 | Placental Lesions in CD-1 Mouse Placenta Following Gestational Exposure to Perfluorooctanoic Acid (PFOA) or Hexafluoropropylene Oxide Dimer Acid (HFPO-DA or GenX). | Toxicol Pathol | 2026 | https://conductscience.org/library/papers/42130276 | PubMed |
| 42100166 | Mosaic pathogenic PRKAG2 variant and pathologic diagnosis of glycogen storage disease in an infant with negative whole-genome sequencing. | JHLT Open | 2026 | https://conductscience.org/library/papers/42100166 | PubMed |
| 40893165 | Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40893165 | PubMed |
| 39604266 | A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. | Mol Ther | 2025 | https://conductscience.org/library/papers/39604266 | PubMed |
| 35715554 | Imaging peripheral nerve micro-anatomy with MUSE, 2D and 3D approaches. | Sci Rep | 2022 | https://conductscience.org/library/papers/35715554 | PubMed |
| 32637453 | A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme. | Mol Ther Methods Clin Dev | 2020 | https://conductscience.org/library/papers/32637453 | PubMed |
| 31660421 | AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice. | Mol Ther Methods Clin Dev | 2019 | https://conductscience.org/library/papers/31660421 | PubMed |
| 31392201 | An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31392201 | PubMed |
| 30809555 | Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease. | Mol Ther Methods Clin Dev | 2019 | https://conductscience.org/library/papers/30809555 | PubMed |
| 28895054 | A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. | Mol Neurobiol | 2018 | https://conductscience.org/library/papers/28895054 | PubMed |
| 27491085 | Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma. | Dis Model Mech | 2016 | https://conductscience.org/library/papers/27491085 | PubMed |
| 26921786 | Neuropathology in respiratory-related motoneurons in young Pompe (Gaa(-/-)) mice. | Respir Physiol Neurobiol | 2016 | https://conductscience.org/library/papers/26921786 | PubMed |
| 24448824 | Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease. | FASEB J | 2014 | https://conductscience.org/library/papers/24448824 | PubMed |
| 23609349 | The brain in late-onset glycogenosis II: a structural and functional MRI study. | J Inherit Metab Dis | 2013 | https://conductscience.org/library/papers/23609349 | PubMed |
| 22993195 | Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease. | FASEB J | 2013 | https://conductscience.org/library/papers/22993195 | PubMed |
| 18648322 | Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. | J Neuropathol Exp Neurol | 2008 | https://conductscience.org/library/papers/18648322 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17510371
GET https://conductscience.org/api/papers/v1/17510371/authors